Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Wire Industries Partners with Birches Health to Create Safer, More Responsible Gaming Environment

WagerWire

Wire Industries, Inc., a technology and media company that owns and operates sports betting marketplace WagerWire, announced today that it has partnered with Birches Health, a leading behavioral healthcare company that specializes in the online and confidential prevention and treatment of problem gambling-related challenges. This partnership complements the work Wire Industries has already done to promote responsible gaming by redefining what it means for bettors to have control over their entertainment time participating in real-money gaming and daily fantasy sports. Through this partnership, Wire Industries will propel awareness of responsible gaming and increase bettors’ access to important guidance and tools to ensure they are better informed and aware of the signs of problem gambling and prepared to take steps to address it if they see themselves or others exhibiting those signs. Wire Industries and Birches Health will work together to create clinical materials tailored to the needs of the modern bettor. In addition, Birches Health clinicians will appear on Wire Industries Spaces interviews held live on X.com, Birches Health content will be integrated across the WagerWire app and specific Birches Health and WagerWire co-created resources and tools will live across each partner’s website. “Wire Industries was created with the sole purpose to empower bettors and create an environment of responsible gaming,” said Wire Industries CEO Zach Doctor. “By working with Birches Health, we join ourselves with another innovative company in the industry that is also doing whatever they can to create more awareness, tools and resources for the bettor all while reinforcing our commitment to responsible gaming. We hope others in the industry see this innovation as a way to better the modern bettor and follow suit.” Birches Health is a modern digital healthcare company specializing in the prevention and treatment of behavioral addictions, with a primary focus on gambling disorder and related mental health issues in the United States. Utilizing a three-tiered strategic approach—education, engagement, and treatment—Birches Health offers free online learning modules, self-assessments, tools, and educational content to promote Responsible Gaming and prevent problem behaviors. For individuals in need, personalized treatment plans are crafted and led by licensed, specialized behavioral health clinicians available 24/7. Dedicated to providing convenient and comprehensive care, Birches Health empowers individuals to address behavioral health challenges effectively. “We applaud WagerWire and their team for a focus on making resources and education available and empowering their users to make healthier lifestyle choices.,” said Elliott Rapaport, Founder of Birches Health. “Partnering with Wire Industries to make sure that treatment options through WagerWire, FantasyWire and its other platforms are available to those who may need them creates a culture of sustainable play for all participants.” As part of this initiative, WagerWire and Birches Health are also exploring opportunities to integrate AI-driven tools and personalized support pathways into the WagerWire platform, further enhancing user education and care accessibility. This partnership will also further Wire Industries as an innovative, forward-thinking disruptor in all aspects associated with the gaming world. About Wire Industries Wire Industries Inc was founded with the mission to bring a more efficient, open, and entertaining market to real money gaming of all types, unlocking value for the entire ecosystem. The company was established in 2021 and owns and operates Wire Technologies and Wire Media Group. Wire Technologies is the company’s marketplace division including WagerWire, FantasyWire, PonyWire and ContestWire, while Wire Media Group operates their media network and affiliate marketing division. You can download their flagship product WagerWire in the Apple App Store and Google Play, and find them @WagerWire on Twitter/X, TikTok and LinkedIn, or @WagerWireLive on Instagram. Wire Industries is dedicated to providing a responsible gaming environment. If you think you or someone you know may have a gambling problem, resources are available. Call 1-800-GAMBLER or reach out to their Chief Responsibly Officer Carolina Young directly at live@wagerwire.com. About Birches Health Birches Health provides modern, clinician-led solutions for Responsible Gaming and Problem Gambling care covered by insurance. For more information, visit Birches Health at bircheshealth.com or email partnerships@bircheshealth.com. Contact Details Sterling Randle srandle@hotpaperlantern.com

January 30, 2025 09:01 AM Eastern Standard Time

Image

IntusCare Celebrates Milestone Year Building Momentum for 2025

IntusCare

IntusCare, a technology leader in the PACE market, celebrated a transformative year in its offerings for PACE (Programs of All-Inclusive Care for the Elderly), underscoring its commitment to supporting value-based care (VBC) models that serve complex senior populations. The company looks to build on the significant momentum in 2025. IntusCare starts the year with additional funding, having recently announced the company raised $11.5 million in a strategic follow-on financing round, bringing total funding to over $27 million. This infusion of capital will fuel the launch of CareHub, a comprehensive care management platform, and support the expansion of IntusCare’s existing suite of Revenue Integrity, Population Health, and Utilization Management solutions. Additionally, the company plans to accelerate its artificial intelligence research, aiming to enhance user experiences for healthcare providers and staff. Notably in 2024, the company announced the launch of two new products and one new service, all specifically designed for PACE. CareHub: The first PACE-specific EMR and practice management system for workflows to manage the VBC model, revolutionizing how interdisciplinary care teams, quality, and compliance managers care for older adults with complex healthcare needs. Intus Revenue Integrity System (IRIS): The first real-time, data-driven risk adjustment system designed specifically for PACE and VBC organizations. IRIS is designed to support PACE and VBC clinical, financial, compliance, and leadership teams to optimize workflows for consistent risk adjustment results. Delegated Utilization Management (UM) Service for PACE: The availability of fractionally-staffed Integrated Care Services (ICS) clinicians and nurses who optimize utilization management for organizations. “This year has been exciting in terms of building a foundation and the momentum to better serve our customers through technology and the expertise we bring to the industry,” said Robbie Felton, CEO and co-founder of IntusCare. “Initially when we started this company during college, we began as a data provider for PACE programs for better care decisions empowered by population health analytics. Now, we’ve grown in scope with delegated services, risk adjustment, and an EMR and practice management system, providing more value to our clients who are empowered to provide even better care for their complex, senior patients.” Much of IntusCare’s growth in scope took place within the last year, propelled by deep partnerships with their customers who shared their needs with the company. The vision for CareHub emerged when customers shared pain points such as reducing staff documentation and administrative burden, integrating disparate data systems, and enabling actionable workflows for interdisciplinary care teams. “Ultimately, we want to be the place where all value-based care organizations that manage risk for complex care come to do their work. CareHub is a key foundation of the ultimate operating system that we're looking to build for the space and community,” said Evan Jackson, co-founder and Chief Operating Officer for IntusCare. Strategic Partnerships Over the last year, IntusCare grew its strategic partnerships, including the addition of new PACE programs as clients along with alliances with other technology companies to improve offerings to customers. IntusCare now serves 70+ PACE organizations across the country, adding 33 new partners in 2024, an increase of ~90% over 2023. This growth is driven by our commitment to both grow alongside our existing partners and expand throughout PACE with the aligned goal of empowering high quality participant care. In addition, IntusCare is breaking down industry silos by prioritizing data access and interoperability through strategic partnerships with leading technology companies. This approach ensures the delivery of impactful, integrated solutions that better serve its customers. An example of how IntusCare is prioritizing interoperability with PACE organizations is through its collaboration with MedVision for seamless data integration, improved care coordination, regulatory and compliance support, and operational and financial efficiencies. Another partnership with Grane Rx will allow their pharmacy solutions to integrate with CareHub supporting medication safety, streamlined workflows, and advanced ePrescribing within the platform for PACE. Thought Leadership Education Providing software solutions is not enough within the complex healthcare environment, including some of the intricacies of PACE. IntusCare used its expertise and connections to support thought leadership educational opportunities to benefit the PACE ecosystem. Chief Population Health Officer Laura Ferrara, an experienced PACE leader, presented at several PACE organization conferences and meetings throughout the year, including a PACE Basics workshop at the National PACE Association’s annual conference in October. In November, IntusCare hosted a virtual conversation on “PACE and the Future of Healthcare Data Interoperability” with leading guests within healthcare and the PACE community. IntusCare CEO Robbie Felton moderated the discussion with Shawn Bloom, CEO and president of the National PACE Association (NPA); Dr. David Feinberg, Chairman of Oracle Health; and Stephanie Rock, Vice President of Product & Client Delivery at IntusCare. Team Growth In order to expand its software and services options, IntusCare strategically grew its team, including the addition of key leadership positions. Bharath Kakarla joined as the Senior Vice President of Engineering to lead the technology team, collaborating closely with product and design counterparts to ensure that IntusCare's products and services align seamlessly with customer needs. Stephanie Rock joined as Senior Vice President of Product and Client Delivery, leading the product and design teams to ensure the company meets the needs of IntusCare’s current and future partners. For more information and to schedule a demo or consultation, reach out through IntusCare’s website. About IntusCare ‍ IntusCare develops innovative predictive analytics platforms aimed at improving geriatric care outcomes. Founded in 2019 by Brown University undergraduate students, IntusCare empowers geriatric care providers to deliver more effective patient management and treatment for dual-eligible seniors – some of the most socially vulnerable and clinically complex individuals in the U.S. healthcare system. Visit our website to learn more intuscare.com. Contact Details Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com Company Website https://intuscare.com/

January 29, 2025 10:00 AM Eastern Standard Time

Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry

Global Markets News

PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN) * continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions. Silexion's latest preclinical findings mark a significant advancement in RNAi therapeutics, with data showing 50% tumor growth reduction and complete necrosis in half of treated tumors after 30 days, sustained therapeutic levels for over 56 days from a single administration, and broad coverage of key KRAS mutations (G12D, G12V, G12R, Q61H, and G13D). These results build upon previous successes, including promising synergy with first-line chemotherapies and the strategic collaboration with Evonik for advanced PLGA microparticle formulation. The precision oncology landscape has witnessed unprecedented consolidation, with Pfizer's $43 billion acquisition of Seagen and AbbVie's $10.1 billion purchase of Immunogen exemplifying the industry's willingness to invest heavily in innovative cancer therapeutics. These transactions reflect a broader industry shift toward precision medicine, particularly in oncology, where targeted therapies command significant premiums. Silexion's emergence as a potentially compelling player stems from its differentiated RNAi approach to targeting one of oncology's most challenging problems, offering broader applicability across multiple KRAS mutations compared to competitors' small molecule inhibitors. The first-generation LODER™ platform has already demonstrated promising Phase 2 results, while the next-generation SIL-204 advances toward clinical trials with successful validation of systemic administration. Notable industry analysts seem to have taken notice, with Maxim Group initiating coverage with a "strong buy" recommendation in November 2024 and an updated price target of $9. As Silexion advances toward clinical trials with SIL-204 and explores expanded development strategies, several key catalysts may lie ahead and could be worth watching closely, including metastasis impact studies, advancement towards next phases of trials, data from additional indications, potential strategic partnerships, and more positioning the company uniquely in the precision oncology landscape at a time when the industry actively seeks innovative solutions for challenging cancers. Click here to Subscribe for more updates like this Read out Previous update regarding Silexion Therapeutics Read out Previous update regarding Silexion Therapeutics >> We Encourage you to read the source news from Silexion: Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models (*)Important Disclaimers & Disclosures: This report is for informational purposes only and should not be considered financial or investment advice. The author is not a registered financial or investment advisor nor does he hold any type of license or engage in any activity that would require one. The content may include forward-looking statements and opinions that may not materialize. Investors should conduct their own due diligence and consult with a qualified investment professional before making any investment decisions. This report was produced by ‘PESG Research’, a content brand which is part of the Wall Street Wire network, a digital coverage and news distribution subscription service and platform operated for commercial, promotional and investor relations purposes. This report contains advertising/promotional content relating to Silexion Therapeutics. Please review our detailed disclosure and disclaimer linked below which details the subscription fees the operators of PESG and the network of brands it is a part of received from Silexion Therapeutics and other customers for coverage, distribution and news promotion services, in accordance with Section 17(b) of the Securities Act. Please review the full disclaimers and disclosures this report is subject to: https://redditwire.com/terms. Contact Details Wall Street Wire Reports Desk* ronald@futuremarketsresearch.com

January 29, 2025 09:24 AM Eastern Standard Time

Centre for Neuro Skills Earns Accreditation in Applied Behavioral Analysis and Training at Three of its Locations

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, has been accredited by the Behavioral Health Center of Excellence (BHCOE) for demonstrating a commitment to the standards of excellence for applied behavior analysis services. The BHCOE Accreditation® distinguishes applied behavior analysis (ABA) therapy providers that demonstrate continuous improvement in applied behavior analysis and dedication. Three of CNS’ locations in Bakersfield and Los Angeles, California, and Irving, Texas have earned this accreditation and have been approved as training sites for behavior analysis students. Since 1980, Centre for Neuro Skills has treated thousands of people whose brain injury deficits include complex behavior challenges. Behavior analysts and therapists are trained in behavior skills, crisis prevention and management, and implementation of comprehensive, interdisciplinary rehabilitation programs. As an accredited training site, students and interns can learn from board-certified behavior analysts to help treat behavior problems. “We are thrilled that our behavior department and treatment program has been recognized as a standard of excellence,” said Chris Persel, Regional Director of Clinical Services and Director of Behavior Programming. “This accreditation opens up more opportunities for behavior analysis students and demonstrates the importance of providing behavioral analysis services to individuals facing a brain injury." *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

January 29, 2025 06:01 AM Pacific Standard Time

Image

Shareholder Group, Detransitioner to Call Out Gender Ideology Harm at Visa, Inc. Annual Meeting on Tuesday

NLPC

National Legal and Policy Center, an investor in Visa, Inc., will present a shareholder proposal at the payment processor’s annual meeting on Tuesday, Jan. 28. The measure asks the company to investigate risks related to its discriminatory pay and benefits policies – specifically addressing where employees affected by gender-switching advocacy have been psychologically or medically harmed, without providing remedial care – and reporting to shareholders why such compensation gaps exist in the company’s policies. Speaking at Visa’s meeting in support of the proposal will be Claire Abernathy, a 20-year-old detransitioner whose therapy, medical and health insurance providers steered her into drastic body altering procedures when she questioned her gender starting at age 12. Ms. Abernathy will address the company’s board of directors and executive leadership, explaining her difficulties in finding medical care and insurance coverage to attempt to repair the damage done to her body. An excerpt from Abernathy’s planned remarks: By age 12 therapists affirmed my feelings about my body and false identity, and made my parents feel like abusive bigots for not immediately affirming me. The therapy was covered by my parents’ health insurance. Alleged medical professionals put me on a menstrual suppression drug, and at 14 I was put on testosterone and underwent a double mastectomy. It took only 8 months between getting referred for therapy and getting my breasts removed. That is an ideological agenda in search of victims, in the name of medicine, and it’s wrong. “By failing to include detransition care, companies like Visa perpetuate the neglect of a vulnerable population,” said Abernathy. “True equity in healthcare means acknowledging the full range of outcomes in gender transitioning treatments, and ensuring that all individuals have access to the care that they need.” In its shareholder proposal, NLPC itemizes numerous graphic, ghastly body-altering procedures that are drawn from Visa’s employee health insurance coverage through CIGNA, which also covers their minor dependents. Besides early-teen mastectomies like what Abernathy was pressured into, Visa also pays for procedures including penectomies, vaginectomies, orchiectomies, and salpingooophorectomies. “Rather than affirming and funding radical medical experiments on workers and their children – which sound more like something out of a horror movie than legitimate health care – Visa needs to just eliminate this coverage,” said Paul Chesser, director of the Corporate Integrity Project for NLPC. “With detransitioner lawsuits spreading across the country against medical providers and health facilities, corporations that sponsor this ‘care’ won’t be far behind in finding themselves in court.” As NLPC points out in its shareholder proposal, the Equal Employment Opportunity Commission considers failure to provide equivalent pay and benefits based on categories including “gender identity” and “sexual orientation” as discriminatory. Even the Securities and Exchange Commission agreed with NLPC that de-transitioning individuals fit under such classifications when considering unfairness in corporate compensation practices, in a decision rendered last year regarding NLPC’s shareholder proposal at Disney. NLPC sponsored similar proposals last year at Johnson & Johnson and PepsiCo. You can read NLPC’s shareholder proposal for Visa at its website. Last year Chesser also composed commentaries for the New York Post and Real Clear Markets that further explained the proposals and their necessity. Founded in 1991, NLPC promotes ethics in public life and government accountability through research, investigation, education, and legal action. ### For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

January 28, 2025 09:00 AM Eastern Standard Time

Deaf Organizations Fund Unveils 2025 Grantees Resourcing Deaf Communities

Communication Service for the Deaf

Deaf Organizations Fund (DOF) proudly announces the selection of four organizations receiving unrestricted grants this month to address the diverse needs of their deaf communities through 2025: Atomic Hands, Deaf Defy, Inc., DEAFinitely, Inc., and The Black Deaf Project. The $100K distributed among these organizations will support accessible educational and multicultural resources, break down healthcare barriers, and expand opportunities for DeafBlind youth, giving grantees the flexibility to direct funding where it is most needed. “As a small, Deaf-run nonprofit, it means so much to see a funder like this one specifically targeting deaf-centric organizations,” said Zaineb Abdulla, Founder of Deaf Defy, Inc. “I love the inclusion of using American Sign Language in all engagement with DOF.” DOF’s second unrestricted Impact Grant for Deaf Organizations received a record-breaking 84 applications from deaf-centric organizations and programs. In alignment with participatory grantmaking, a community-led grant review committee shaped the decision-making process. They evaluated all eligible applications and supported DOF in making the final award decisions. “Our trust-based approach to grantmaking has been met with incredible support, and we’re excited to continue working alongside organizations that are igniting meaningful change in our deaf communities,” said Sasha Ponappa, Executive Director of DOF. "We are also deeply grateful for ongoing support from our donors and partners, whose contributions ensure DOF's ability to fund and resource deaf organizations." As DOF enters its sixth funding cycle, the team is also focused on expanding resources beyond grant dollars. This support includes grantee coaching, technical assistance, the development of an accessible training program and community hub for deaf organization leaders, and advocacy for disability justice within the philanthropic sector. To learn more about DOF’s impact and the work of its grantee organizations, interested parties are invited to view the newly released Social Impact Report. Funders and supporters who wish to contribute to DOF’s mission are encouraged to reach out directly. About Deaf Organizations Fund (DOF): DOF was established in 2021 by its fiscal sponsor, Communication Service for the Deaf, offering fully accessible grants and resources to deaf-centric organizations and programs based in the United States. To date, DOF has distributed nearly $500K in grant funds among 27 deaf-centric organizations and programs. Contact Details Avi Haimowitz, Director of Development dof@deaforganizationsfund.org Company Website https://deaforganizationsfund.org/

January 27, 2025 11:33 AM Eastern Standard Time

News Release

Groundwork BioAg and Sustainable Travel International Partner to Offer Carbon Dioxide Removal Credits for Tourism

Groundwork BioAg

Groundwork BioAg ®, the world’s largest producer of mycorrhizal inoculants, announced a new partnership with Sustainable Travel International, a global leader in sustainable tourism solutions, to offer travelers and businesses access to premium carbon dioxide removal (CDR) credits, based on the application of mycorrhizal fungi in cropland. Mycorrhizal inoculants are applied in agricultural soils to improve crop yields, save fertilizer, reduce plant stress, and improve soil health – but at the same time, these microbial products act as a natural pathway to permanently sequester carbon. This partnership aligns with Sustainable Travel International’s mission to provide programs that help travelers, businesses and destinations protect the environment, preserve cultural heritage and promote economic development. Groundwork BioAg's Rootella Carbon™ program offers high-integrity, high-volume, durable carbon credits that are independently certified and approved, providing a reliable solution for organizations seeking to meet their net-zero pledges responsibly. "By adding Rootella Carbon to our Climate Impact Portfolio, we reaffirm our commitment to promote holistic environmental stewardship so our members can visit – and protect – the places they love,” said Paloma Zapata, CEO of Sustainable Travel International. “This innovative, nature-based solution aligns with our mission to help the travel industry address its carbon liability while directly improving soil health around the world.” Sustainable Travel International’s Climate Impact Portfolio includes a wide variety of projects in different locations that generate carbon credits as they reduce or remove emissions. The portfolio includes a mix of high-quality forestry, clean/efficient energy, blue/teal carbon, and innovative climate tech projects. The demand for high-quality carbon credits is growing rapidly, with two-thirds of the world's largest companies with net-zero targets using carbon offsets to help meet their climate goals. Rootella Carbon credits stand out among durable CDR credits as a scalable solution that not only sequesters carbon in the soil but also improves crop yields, reduces chemical fertilizer use, mitigates plant stress and supports regenerative agricultural practices. Dan Grotsky, co-founder and chief growth officer of Groundwork BioAg, said, "This collaboration not only validates the effectiveness of our Rootella Carbon program but also demonstrates the travel industry's commitment to sustainable practices. Together, we are paving the way for significant carbon sequestration by enabling travelers and rewarding farmers around the world – while contributing to a healthier planet." Rooted in Groundwork BioAg’s history of helping growers improve the productivity and profitability of their farms, this partnership now gives travelers the opportunity to directly support farmers for their land stewardship while reducing their own carbon footprint. Currently under validation within the Verra VM0042 v2.0 protocol, Rootella Carbon offers farmers the opportunity to earn up to 70% of net proceeds from carbon credit sales, making it an attractive option for growers looking to diversify their income streams. This innovative approach unlocks compensation for regenerative growers who would otherwise be ineligible for carbon credits, while incentivizing conventional farmers to adopt regenerative practices. For more information about Groundwork BioAg and the Rootella Carbon program, visit GroundworkBioAg.com. About Groundwork BioAg Groundwork BioAg, a leading bioagriculture company, produces cost-effective mycorrhizal inoculants at scale to tackle food insecurity and climate change. Groundwork BioAg’s nature-based carbon dioxide removal solution leverages mycorrhizae as carbon’s main pathway into the soil and is supercharging permanent carbon sequestration on millions of hectares of commercial and regenerative farms globally. We envision the world’s cropland regenerating with mycorrhizae and every farmer benefiting from higher yields, healthier soils, fertilizer reduction, and verifiable, premium carbon credit revenue – without altering cultivation practices. Nature’s most potent carbon removal solution is now in every farmer’s hands. For more information, visit groundworkbioag.com or groundworkbioag.com/rootella-carbon. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

January 22, 2025 10:32 AM Central Standard Time

Cortland Biomedical Secures FDA Registration, Expanding Role as a Trusted Contract Manufacturer for Medical Device OEMs

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of global engineering, design, and manufacturing capabilities, is proud to announce its FDA registration, marking a significant milestone in the company’s evolution. This new designation positions Cortland Biomedical as a full-service contract manufacturer and reinforces the company’s unwavering commitment to delivering the highest standards of quality, compliance, and service to its medical device customers. As an FDA-registered contract manufacturer, Cortland Biomedical will better support its clients in highly regulated markets, particularly in the orthopedic sector, where precision and reliability are critical. The FDA registration, partnered with ISO 13486:2016 compliance, ensures that Cortland Biomedical operates under a robust Quality Management System (QMS) that meets stringent regulatory requirements, offering its customers peace of mind in the safety and performance of their devices. “FDA registration is a game-changer for Cortland Biomedical and our customers,” said Tara Yunkunis, Senior Business Development Manager, Cortland Biomedical. “This milestone underscores our dedication to maintaining world-class quality systems and compliance practices. As a contract manufacturer, we can now take a more active role in helping our customers bring innovative medical devices to market faster and with greater confidence.” With extensive expertise in the design and production of advanced biomedical textiles, Cortland Biomedical specializes in creating tailored solutions for a range of applications, including orthopedics, sports medicine, cardiovascular, robotic surgery, general surgery, and others. This expanded capability allows it to now partner with OEMs from initial concept through full-scale manufacturing, providing a seamless, forward-integrated approach to medical device development. For more information about Cortland Biomedical and its expanded capabilities as an FDA-registered contract manufacturer, visit cortlandbiomedical.com or come see the team in booth 2127 at the upcoming MD&M West show in Anaheim, CA. Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical's unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers' complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 22, 2025 10:00 AM Eastern Standard Time

How Monogram’s (NASDAQ: MGRM) Dynamic Approach To Robotics Could Help Reshape the Future Of Orthopedics

Benzinga

By Meg Flippin Benzinga Robots are becoming increasingly more common in the operating room, but just how automated are they? Monogram Orthopedics Inc. (NASDAQ: MGRM) would argue we have a long way to go before the full potential of robotic technology is fully tapped. The proliferation of robotics and increasing utilization is, at this point, likely a foregone conclusion. After all, some estimates predict that 50% of all knee procedures will be robotic by 2027, up from 11% in 2019. Yet despite the proliferation of AI and fully autonomous robotics in nearly every aspect of daily life, the surgical equipment currently in use for common orthopedic procedures is still reliant on surgeon skill. Monogram’s mBôs robotic technology aims to increase automation and reduce reliance on user skills. As a pioneer in autonomous saw-based cutting, the company has applied decades of robotics experience to amass an extensive portfolio of innovation, including some 23 patent applications in process. The majority of procedures done today combine manual surgery with robotics. The process can still rely heavily on surgeon skill to safely execute the surgery. Monogram’s mBôs aims to minimize direct surgeon contact with the robot mounted tools and hopes to provide surgeons a more autonomous platform for precise surgical bone cuts based on preoperative planning. Monogram’s autonomous robotics platform captured the attention of investment bank Roth Capital Partners, which recently initiated coverage of the company, noting mBôs simplifies surgery as a likely direct challenge to the dominant players in the space. “While orthopedic surgeons remain characteristically conservative, the clinical case for robotics technology is building, and robotics are changing market dynamics,” according to an analyst report compiled by Roth Managing Director Jason Wittes. “We anticipate adoption surpassing 50% over the next five years, and thus see significant strategic value in emerging robotics platforms such as MGRM's mBôs that can challenge MAKO’s dominance.” In addition, Monogram reports its technology pipeline is robust. It plans to introduce mVision in the future, which could enable faster registration and further optimize surgical time compared to competitors. Combination Of Advanced Technologies To Deliver Results Monogram leverages AI and robotics to develop state-of-the-art robots that can assist surgeons with knee reconstruction and, in the future, other procedures like hips, shoulders, ankles and spine. Monogram’s robotic systems aim for precise virtual assessment of laxity values to determine the potential clinical impact of planned resections. Its technology enables surgeons to place implants virtually before cutting to assess the impact of various resections on knee laxity with a target to achieve submillimeter bone cuts. These tools could dramatically simplify the complexity of joint reconstruction in the future. Monogram hopes the mBôs automation could increase throughput and hopes to reduce clinical risk with a planned clinical study to validate. The goal is for the robot to be easy to use and to lower the learning curve for surgeons. With accurate robotics, precision machine cuts can help enable the use of press-fit implants, eliminating the need for cement. Unlike traditional implants, press-fit implants rely on the patient’s bone to hold the implant in place instead of relying on cement. Natural biologic fixation could reduce the risk of the implant becoming loose for younger active patients as the cement breaks down over time. Showing Off The Tech At HQ Monogram’s unique approach to robotics was on display during an analyst meeting and demo day held in 2024 at the company’s cadaver lab and headquarters in Austin, Texas. Monogram executives – including CEO Ben Sexson, Founder and Chief Medical Officer Dr. Douglas Unis, Chief Technology Officer Dr. Kamran Shamaei and Chief Financial Officer Noel Knape – were on hand along with other senior management team members to provide an overview of the company's progress in combining advanced machine vision, AI and next-generation robotics to improve surgeries and patient outcomes. “We were extremely impressed with the management team, including founder Doug Unis, and the successful product Demonstration of the mBôs Precision Robotic Surgical System in a world-class cadaver lab,” said Dallas Salazar, Doctor Group investor. “The hands-free, fully active system demonstrated to us the ease of use and simplicity that was operated by the founder’s 11-year-old daughter giving more confidence of commercialization and acceptance in the orthopedic robotics community once approved. We believe there is clearly a disruptor in this space that is now bringing a product solution architecture to enable patient-optimized orthopedic implants at scale utilizing artificial intelligence and next-generation robotics.” Market Direction The company believes that the future of the market for robotics is bright. With continued robotic adoption driven by patient outcomes and healthcare providers, it believes robotics are likely to become increasingly autonomous. Given the advancements made in AI and robotics, the systems in place today may still be relatively constrained by a reliance on the precision of individual surgeons. The full potential of robotics could be realized across myriad industries. With the anticipated growth in surgical procedures and critical patient and healthcare business outcomes at stake, coupled with a declining number of orthopedic surgeons, automation could be an answer to the growing demand. Monogram aims to introduce an approach to enabling true automated robotic precision that has the potential to transform the way surgeons around the world perform knee replacements and other orthopedic procedures. Featured photo by SOMKID THONGDEE on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 22, 2025 08:45 AM Eastern Standard Time

Image

1 2 3 4 5 ... 315